NCT04105920Active, not recruiting
Evaluation of the Interest of Hyaluronic Acid in the Preservation of Sexual Function During Prostate Curietherapies
Phase III Trial Randomized to Evaluate the Interest of Hyaluronic Acid in the Preservation of Sexual Function During Prostate Curietherapies
Source: ClinicalTrials.gov · Last updated 24 Jun 2025
Brief summary (registry, in English)
Prostate cancer is the most common cancer in humans, but low mortality, around 10 / 100,000 patients / year. It differs from other cancers by its high rate of cure, as well as a long term survival. Numerous treatment techniques are available and of comparable effectiveness: as a result it must be given importance to the short and long term side effects of these different treatments. Prostate brachytherapy with permanent implants is thus one of the standard techniques for the treatment of localized prostate cancers of favorable grades (WHO grade 1-2). In comparison with prostatectomy and RTE, brachytherapy allows low rates of long-term urinary toxicities, and comparable rates of erectile function preservation. With regard to erectile dysfunction, their pathophysiology after irradiation is complex and poorly understood, including damage to the erector apparatus, innervation, vascularization, and of course the level of libido. As an example, the radiotherapy team of the Lyon Sud hospital showed that the delivering a the lowest dose of radiation to the pudendal arteries and to the penile bulb during RTE, leads to erectile preservation rates comparable with those from the literature with nearly 85% of patients with erectile function retained at 2 years . They were also able to retrospectively show that a lower dose to the pudendal arteries correlated with better erectile function during brachytherapy. The brachytherapy procedure requires general anesthesia and endorectal ultrasound, which are optimal conditions for injecting hyaluronic acid between the prostate, rectum, and pudendal arteries. This gesture has shown to induce very few morbidity. They want to demonstrate that the injection of hyaluronic acid during prostate brachytherapy will reduce the radiation dose to the pudendal arteries and penile bulb, and thus improve the rate of preservation of erectile function in selected patients. This randomized phase III study comparing dyserection rates after CT performed with (Arm A) and without (Arm B) injection of HA, in a patient population without erectile dysfunction before treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- First submitted
- 10 Sept 2019
- Start date
- 5 Oct 2021
- Primary completion date
- 5 Apr 2027
- Lead sponsor
- Hospices Civils de Lyon
- Diseases
- Prostate cancer
- NCT number
- NCT04105920
What you commit to
- Study type: Interventional
- Planned participants: 162
- From 5 Oct 2021 to the primary completion date, 5 Apr 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of abdominal or pelvic irradiation
- Anterior treatment for prostate cancer, including hormone therapy with LHRH analogue or GnRH antagonist.
- History of prostate resection, not allowing brachytherapy seeds implantation.
- Uncontrolled cancer (except basal cell skin cancer)
- Allergy to hyaluronic acid
Other
- Nodal or distant metastatic evolution
- Current clinical study that may interfere with this study
- Patient unable to complete a self-administered questionnaire and understand the ins and outs of the trial
- Major patients protected by law
Who the study is looking for
- Patients aged 18 to 80 years old.
- Patients over 75 years old must have a G8 score ≥ 14 or oncogeriatric assessment.The geriatrician's expertise will validate the brachytherapy treatment.
- Karnofsky performance status ≥ 60% (ECOG performance status 0-2)
- Patients diagnosed with histologically proven localized prostate adenocarcinoma
- Prostate cancer eligible for brachytherapy according to the following criteria:
- at. Low risk prostate cancer: Gleason score \<7 and PSA \<10 ng / ml AND cT1-cT2a
- Intermediate risk prostate cancers with on or two adverse factor: Gleason score = 7 (3 + 4) OR PSA 10-15ng / ml OR cT2b-cT2c / ml
- less than 50% positive biopsies
- Volume of the prostate \<60 cc
- No middle lobe
- IPSS \<15/35
- Initial IIEF5 score, no treatment, greater than or equal to 20/25
- Patient able to sign an informed consent form
- Patient benefiting from a social insurance system or similar system
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Jean François Leclerc Coordinator of this site? Confirm its status | Dijon | France | Unknown status |
| Radiothérapie, Hôpital A. Michallon, CHU de Grenoble Coordinator of this site? Confirm its status | Grenoble | France | Unknown status |
| Centre Hospitalier Lyon-Sud Coordinator of this site? Confirm its status | Pierre-Bénite | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.